## SUMMARY OF SAFETY AND EFFECTIVENESS

**SPONSOR:** 

Biomet, Inc.

P.O. Box 587

Airport Industrial Park

Warsaw, Indiana 46581-0587

**CONTACT PERSON:** 

Tracy J. Bickel

**DEVICE NAME:** 

Ti-MAX Protrusio Cage

**CLASSIFICATION NAME:** 

Hip joint metal/polymer semi-constrained

cemented prosthesis (88.3350)

INTENDED USE: The Protrusio implants are intended for use in reconstruction of the hip joint due to disease, deformity of trauma. The devices are intended for general use in skeletally mature individuals undergoing primary and/or secondary revision surgery. The device is a single use implant. The Protrusio Cage is to be used in conjunction with any commercially available polyethylene acetabular cup.

**DEVICE DESCRIPTION:** This series of four anatomic protrusio cages comes in sizes 52mm-64mm in four millimeter increments. Each cage has two iliac flanges positioned superiorly and one ischial flange positioned inferiorly that provide supplemental screw fixation holes for attachment to the ilium and ischium. These cages, once positioned in the acetabulum and attached to the ilim and ischium, provide structural integrity to an otherwise structurally compromised joint. The improved acetabular construct gained by attaching the device provides a much better site for installation of the functional acetabular bearing surface. The material, CP Titanium, was chosen so that the flanges can be bent intra-operatively in order to match the device to the geometry of the pelvis.

In cases where bony defects or voids exist, optional augments with a grit blast finish can be utilized to help provide additional structural support. The augments are attached to the cage by means of a locking screw.

This device is intended for cemented application.

## **POTENTIAL RISKS:**

The potential risks associated with this device are the same as with any joint replacement device. These include, but are not limited to:

Fracture of the component Cardiovascular disorders

Bone fracture Hematoma

Implant loosening/migration

Blood vessel damage

Soft tissue imbalance

Nerve damage

Deformity of the joint Tissue growth failure Delayed wound healing Metal sensitivity Excessive wear
Infection
Dislocation
Breakdown of the porous surface

## SUBSTANTIAL EQUIVALENCE:

Direct comparison was made with the following predicates:

- 1) Modular Protrusio Cage (K990032): Biomet, Inc.
- 2) Recovery Protrusio Cage (971890): Biomet, Inc.
- 3) Modular Acetabular Reconstructive System (M.A.R.S.) (K911718): Biomet, Inc.

All aforementioned products are manufactured in Warsaw, IN.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## JUL 2 0 2000

Ms. Tracy J. Bickel Regulatory Specialist Biomet, Inc., P.O. Box 587 Warsaw, Indiana 46581-0587

Re: K001376

Trade Name: Ti-Max Protrusio Cage

Regulatory Class: II Product Code: JDI Dated: April 28, 2000 Received: May 1, 2000

Dear Ms. Bickel:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Dinne R. Lochner.

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

		Page	of	· · · · · · · · · · · · · · · · · · ·
510(k) Number (if known): <u>Koo i</u> Device Name: Recovery Protrusio Ca <sub>t</sub> Indications for Use:				
The Protrusio implants are intended for disease, deformity of trauma. The deventure individuals undergoing primar a single use implant. The Protrusio Commercially available polyethylene a	vices are intende y and/or second age is to be used	ed for general us lary revision sur	se in skeletall gery. The de	y
•				
		•		
		•		
(PLEASE DO NOT WRITE BELOW IF NEEDED)	THIS LINE –	CONTINUE OF	N ANOTHEI	R PAGE
Concurrence of CDRH, Office of Dev	vice Evaluation	(ODE)		
Prescription Use X (Per 21 CFR 801.109)	OR	Over-The-Co (Optional Fo	ounter Use_ ormat 1-2-96	)
		DOMAN ON R	. Joch	nel.
		(Division Sign-O	ff)	Devices
	•	510(k) Number <u>k</u>	<00137 Co	
		310(K) Number 3		